EUVIMEDDescubrir EUVIMED
Open access · CC BY-NC-ND 4.0

Cellular Nanoparticles Treat Coronavirus Infection in Vivo

Yiyan Yu iD, Daniela Silva-Ayala, Zhidong Zhou, Yifei Peng, Ronnie H Fang iD, Weiwei Gao iD, Anthony Griffiths, Liangfang Zhang iD

Nano Letters · 2024-11-27 · 24 (47) · 15136-15141

DOI: 10.1021/acs.nanolett.4c04653 ↗

At a glance

Journal article in Nano Letters, published online on 2024-11-13. Written by Yiyan Yu and 7 co-authors. Institution: Aiiso Yufeng Li Family Department of Chemical and Nano Engineering, Shu and K.C. Chien and Peter Farrell Collaboratory, University of California San …. Major MEDLINE topics: Nanoparticles, SARS-CoV-2, COVID-19, Spike Glycoprotein, Coronavirus. Cited 5 times so far (Crossref); 38 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Defense Threat Reduction Agency.

ResumenSubjectsDatos bibliográficosCiteRelated studies

Abstract (original language)

Cellular nanoparticles (CNPs), which refer to nanoparticles coated with natural cell membranes, are promising for neutralizing pathological agents. Here, we use CNPs as a medical countermeasure against the infection of SARS-CoV-2 variants in an animal model. CNPs comprise polymeric cores coated with the plasma membranes of human macrophages. The resulting nanoparticles (MΦ-NPs) act as host cell decoys to intercept SARS-CoV-2 and block its cellular entry, thus inhibiting subsequent viral infection. Our findings indicate that MΦ-NPs bind to the spike proteins of SARS-CoV-2 variants in a dose-dependent manner and inhibit the infectivity of live viruses. In hamsters infected with SARS-CoV-2 variants, MΦ-NPs significantly reduce the viral burden in the lungs, demonstrating their effectiveness in inhibiting viral infectivity in vivo. Furthermore, MΦ-NPs are primarily taken up by alveolar macrophages without inducing noticeable adverse effects. Given the crucial role of macrophages in viral infections, MΦ-NPs present a promising approach to combating emerging viral threats.

Subjects

MeSH terms (MEDLINE)

NanoparticlesSARS-CoV-2COVID-19Spike Glycoprotein, CoronavirusAnimalsHumansCricetinaeMacrophagesLungMacrophages, AlveolarAntiviral AgentsCOVID-19 Drug TreatmentDisease Models, AnimalChlorocebus aethiopsVirus InternalizationVero Cells

Author keywords

antiviralbiological neutralizationcell membrane coatingcellular nanoparticlecoronavirus

Substances

Spike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Antiviral Agents

Authors and institutions

  • Aiiso Yufeng Li Family Department of Chemical and Nano Engineering, Shu and K.C. Chien and Peter Farrell Collaboratory, University of California San Diego, La Jolla, California 92093, United States.
  • Department of Microbiology and National Emerging Infectious Diseases Laboratories, School of Medicine, Boston University, Boston, Massachusetts 02115, United States.
  • Laboratory for Infectious Disease Research and Department of Molecular Microbiology and Immunology, School of Medicine, University of Missouri, Columbia, Missouri 65211, United States.

ORCID profiles: Yiyan Yu, Ronnie H Fang, Weiwei Gao, Liangfang Zhang

Funding

  • Defense Threat Reduction Agency

Cite

APA

Yu, Y., Silva-Ayala, D., Zhou, Z., Peng, Y., Fang, R. H., Gao, W., Griffiths, A., & Zhang, L. (2024). Cellular Nanoparticles Treat Coronavirus Infection in Vivo. Nano Letters, 24(47), 15136-15141. https://doi.org/10.1021/acs.nanolett.4c04653

Vancouver

Yu Y, Silva-Ayala D, Zhou Z, Peng Y, Fang RH, Gao W, et al. Cellular Nanoparticles Treat Coronavirus Infection in Vivo. Nano Letters. 2024;24(47):15136-15141. doi:10.1021/acs.nanolett.4c04653

BibTeX
@article{Yu2024,
  author = {Yu, Yiyan and Silva-Ayala, Daniela and Zhou, Zhidong and Peng, Yifei and Fang, Ronnie H and Gao, Weiwei and Griffiths, Anthony and Zhang, Liangfang},
  title = {Cellular Nanoparticles Treat Coronavirus Infection in Vivo},
  journal = {Nano Letters},
  year = {2024},
  volume = {24},
  number = {47},
  pages = {15136--15141},
  doi = {10.1021/acs.nanolett.4c04653}
}
Start for free →